Bergenbio ASA Market Cap ($7.75 Million)
Market Cap & Net Worth: Bergenbio ASA (BGBIO)
Bergenbio ASA market cap. Bergenbio ASA (OL:BGBIO) has a market capitalization of $7.75 Million (Nkr73.62 Million) as of November 6, 2026. Listed on the OL stock exchange, this Norway-based company holds position #27550 globally and #249 in its home market, demonstrating a -61.29% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bergenbio ASA's stock price Nkr0.47 by its total outstanding shares 156641128 (156.64 Million). Also see Bergenbio ASA cash conversion from operations for how efficiently the company converts equity into cash flow.
Bergenbio ASA Market Cap History (2017–2025)
Bergenbio ASA market cap history from 2017 to 2025. Data shows change from $28.97 Billion to $7.75 Million (-61.96% CAGR). Check Bergenbio ASA stock quote for real-time trading data and today's change.
Bergenbio ASA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bergenbio ASA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Bergenbio ASA growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
159.02x
Bergenbio ASA's market cap is 159.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $37.37 Billion | $2.33 Million | -$191.75 Million | 16002.52x | N/A |
| 2019 | $34.08 Billion | $8.90 Million | -$199.28 Million | 3828.89x | N/A |
| 2020 | $45.82 Billion | $601.00K | -$257.03 Million | 76246.49x | N/A |
| 2021 | $28.86 Billion | $774.00K | -$309.36 Million | 37287.69x | N/A |
| 2022 | $10.63 Billion | $389.00K | -$302.12 Million | 27328.10x | N/A |
| 2023 | $458.23 Million | $354.00K | -$190.40 Million | 1294.44x | N/A |
| 2024 | $134.85 Million | $848.00K | -$139.28 Million | 159.02x | N/A |
Competitor Companies of BGBIO by Market Capitalization
Companies near Bergenbio ASA in the global market cap rankings as of November 6, 2026. Also see total assets of Bergenbio ASA for a full breakdown of the balance sheet.
Key companies related to Bergenbio ASA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Bergenbio ASA (2017–2025)
Market capitalization of Bergenbio ASA from 2017 to today. Between 2017 and today, Bergenbio ASA's market cap moved from $28.97 Billion to $ 7.75 Million, with a yearly change of -61.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | Nkr7.75 Million | -94.25% |
| 2024 | Nkr134.85 Million | -70.57% |
| 2023 | Nkr458.23 Million | -95.69% |
| 2022 | Nkr10.63 Billion | -63.17% |
| 2021 | Nkr28.86 Billion | -37.02% |
| 2020 | Nkr45.82 Billion | +34.47% |
| 2019 | Nkr34.08 Billion | -8.80% |
| 2018 | Nkr37.37 Billion | +28.99% |
| 2017 | Nkr28.97 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Bergenbio ASA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.75 Million USD |
| MoneyControl | $7.75 Million USD |
| MarketWatch | $7.75 Million USD |
| marketcap.company | $7.75 Million USD |
| Reuters | $7.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bergenbio ASA
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory disease in Norway. It develops BGBIL025, a JAK2 inhibitor indicated, which is in Ph1b/2a for treatment of the bone marrow disorder myelofibrosis. The company was incorporated in 2007 and is based in Bergen, Norway.